|
Index | - | P/E | - | EPS (ttm) | - | Insider Own | 9.03% | Shs Outstand | 41.68M | Perf Week | -11.76% |
Market Cap | 475.06M | Forward P/E | - | EPS next Y | -0.44 | Insider Trans | -0.22% | Shs Float | 31.91M | Perf Month | -8.46% |
Income | - | PEG | - | EPS next Q | -0.22 | Inst Own | 76.20% | Short Float | 1.28% | Perf Quarter | -8.31% |
Sales | - | P/S | - | EPS this Y | -38.90% | Inst Trans | 0.16% | Short Ratio | 7.30 | Perf Half Y | -13.12% |
Book/sh | 7.35 | P/B | 1.53 | EPS next Y | 73.70% | ROA | - | Target Price | - | Perf Year | - |
Cash/sh | 6.92 | P/C | 1.63 | EPS next 5Y | - | ROE | - | 52W Range | 11.21 - 19.00 | Perf YTD | -4.17% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -40.74% | Beta | - |
Dividend % | - | Quick Ratio | 55.90 | Sales past 5Y | - | Gross Margin | - | 52W Low | 0.45% | ATR | 0.70 |
Employees | 41 | Current Ratio | 55.90 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 37.80 | Volatility | 6.00% 5.47% |
Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | -189.00% | Profit Margin | - | Rel Volume | 0.88 | Prev Close | 11.63 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 55.94K | Price | 11.26 |
Recom | 1.60 | SMA20 | -6.45% | SMA50 | -9.71% | SMA200 | -13.99% | Volume | 49,322 | Change | -3.18% |
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada. | ||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite